GV-971: Clinical Trials

2 trials of GV-971, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 suspended. 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 32Completed 1, Suspended 1

Follow GV-971: new trials by email Literature Review of GV-971 trials Research Report on GV-971

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
GV-971, Placebo - Alzheimer Disease
Phase 3SuspendedGreen Valley (Shanghai) Pharmaceuticals Co., Ltd.20462020-10-272022-11-23
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
Sodium oligo-mannurarate 900mg, Placebo - Mild to Moderate Alzheimer Disease, Cognitive Impairment
Phase 3CompletedShanghai Greenvalley Pharmaceutical Co., Ltd.8182014-04-012018-10-10

Conditions studied

Alzheimer Disease (1)  ·  Cognitive Dysfunction (1)

Sponsors

Green Valley (Shanghai) Pharmaceuticals Co., Ltd. (1)  ·  Shanghai Greenvalley Pharmaceutical Co., Ltd. (1)

Countries

China (2)  ·  Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Hong Kong (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Taiwan (1)  ·  United States (1)

Results publications

PMID 33475022